Israel - ebraică - Ministry of Health

eli lilly israel ltd, israel - ixekizumab - תמיסה להזרקה - ixekizumab 80 mg / 1 ml - ixekizumab

Israel - ebraică - Ministry of Health

novartis israel ltd - brimonidine tartrate; brinzolamide - brimonidine tartrate 2 mg/ml; brinzolamide 10 mg/ml - brinzolamide, combinations

Israel - ebraică - Ministry of Health

abic marketing ltd, israel - modafinil - קפליות - modafinil 100 mg - modafinil

Israel - ebraică - Ministry of Health

abic marketing ltd, israel - modafinil - קפליות - modafinil 100 mg - modafinil

Israel - ebraică - Ministry of Health

dexcel ltd, israel - betamethasone as dipropionate; calcipotriol as hydrate - ג'ל - betamethasone as dipropionate 0.5 mg / 1 g; calcipotriol as hydrate 50 mcg / 1 g - betamethasone - betamethasone - topical treatment of psoriasis vulgaris on the scalp and topical treatment of mild to moderate “non-scalp” plaque psoriasis vulgaris in adults 18 years of age and older.

Israel - ebraică - Ministry of Health

bayer israel ltd - drospirenone; ethinylestradiol - טבליות מצופות פילם - drospirenone 3 mg; ethinylestradiol 0.02 mg - drospirenone and estrogen - drospirenone and estrogen - - oral contraception. - treatment of moderate acne vulgaris in women who seek oral contraception. - treatment of symptoms of premenstrual dysphoric disorder (pmdd ) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms ( premenstrual syndrome ).

Israel - ebraică - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - medroxyprogesterone acetate - תרחיף להזרקה - medroxyprogesterone acetate 104 mg / 0.65 ml - medroxyprogesterone - medroxyprogesterone - * sayana is indicated for long-term female contraception. each subcutaneous injection prevents ovulation and provides contraception for at least 13 weeks (+/- 1 week). however, it should be taken into consideration that the return to fertility (ovulation) may be delayed for up to one year .since loss of bone mineral density may occur in females of all ages who use sayana long-term, a risk/benefit assessment, which also takes into consideration the decrease in bone mineral density that occurs during pregnancy and/or lactation, should be considered.* use in adolescents (12-18 years)in adolescents, use of sayana is only indicated when other contraceptive methods are considered unsuitable or unacceptable, due to unknown long-term effects of bone loss associated with sayana during the critical period of bone accretion.sayana has not been studied in women under the age of 18 years but data is available for intramuscular medroxyprogesterone acetate in this population.

Israel - ebraică - Ministry of Health

המרכז לקוסמטיקאיות בעמ - הזנה לפנים

Israel - ebraică - Ministry of Health

אינטרביוטי קוסמטיקס ישראל בעמ - ריכוך השיער

Israel - ebraică - Ministry of Health

אינטרביוטי קוסמטיקס ישראל בעמ - שיפור מראה העור